Author

George C. Wang

Institution: Johnson & Johnson (United States)

Observed institution: Johnson & Johnson (United States)

OpenAlex ID: A5137085335

Age and frailty analyses of transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone (Rd) and bortezomib-Rd (VRd).

2026 · Christopher P. Venner, Sonja Zweegman, et al. · Journal of Clinical Oncology

Works count: 1

Citation count:

H-index:

I10-index: